← All trials
NCT07104162
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2025
- Primary completion
- Jul 30, 2026
- Completion date
- Dec 23, 2026
- First posted
- Aug 5, 2025
- Last posted
- Nov 25, 2025
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qpex Biopharma, Inc.Lead sponsor
- Orlando Clinical Research CenterOfficial
- University of MiamiOfficial
- Department of Health and Human ServicesCollaborator
- ShionogiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.